192 related articles for article (PubMed ID: 27171241)
1. Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights.
Fabbrocini G; Panariello L; Caro G; Cacciapuoti S
Skin Appendage Disord; 2015 Mar; 1(1):31-7. PubMed ID: 27171241
[TBL] [Abstract][Full Text] [Related]
2. Reducing Acneiform Rash Induced by EGFR Inhibitors With Honeysuckle Therapy: A Prospective, Randomized, Controlled Study.
Liu Z; Tian T; Wang B; Lu D; Ruan J; Shan J
Front Pharmacol; 2022; 13():835166. PubMed ID: 35250582
[No Abstract] [Full Text] [Related]
3. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
Yuan C; Wang B
J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
[TBL] [Abstract][Full Text] [Related]
4. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
5. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512).
Nishino K; Fujiwara Y; Ohe Y; Saito R; Miyauchi E; Kobayashi T; Nakai Y; Takahashi T; Shibata T; Hamaguchi T; Kikuchi K; Yamazaki N; Fukuda H; Nozawa K; Kiyohara Y
Support Care Cancer; 2021 May; 29(5):2327-2334. PubMed ID: 32918131
[TBL] [Abstract][Full Text] [Related]
6. Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors.
Nakahara T; Moroi Y; Takayama K; Itoh E; Kido-Nakahara M; Nakanishi Y; Furue M
Onco Targets Ther; 2015; 8():259-63. PubMed ID: 25670908
[TBL] [Abstract][Full Text] [Related]
7. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors.
Brodell LA; Hepper D; Lind A; Gru AA; Anadkat MJ
J Cutan Pathol; 2013 Oct; 40(10):865-70. PubMed ID: 23941617
[TBL] [Abstract][Full Text] [Related]
8. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
Gorji M; Joseph J; Pavlakis N; Smith SD
Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
[TBL] [Abstract][Full Text] [Related]
9. Management of dermatologic toxicities associated with monoclonal antibody epidermal growth factor receptor inhibitors: A case review.
Leporini C; Saullo F; Filippelli G; Sorrentino A; Lucia M; Perri G; Gattuta GL; Infusino S; Toscano R; Dima G; Olivito V; Paletta L; Bottoni U; De Sarro G
J Pharmacol Pharmacother; 2013 Dec; 4(Suppl 1):S78-85. PubMed ID: 24347989
[TBL] [Abstract][Full Text] [Related]
10. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
11. Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance.
Takahashi H; Asaka J; Tairabune T; Ujiie H; Matsuura Y; Nihei S; Kimura T; Chiba T; Kudo K
J Clin Pharm Ther; 2021 Oct; 46(5):1404-1411. PubMed ID: 34145608
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
13. Effect of risk factors for acneiform rash induced by anti-epidermal growth factor receptor antibody drugs on survival: a retrospective observational study.
Takahashi H; Yaegashi Y; Saito Y; Nihei S; Tairabune T; Ujiie H; Asaka J; Kudo K
J Pharm Health Care Sci; 2022 Sep; 8(1):22. PubMed ID: 36045384
[TBL] [Abstract][Full Text] [Related]
14. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects.
Recuero JK; Fitz JR; Pereira AA; Bonamigo RR
An Bras Dermatol; 2023; 98(4):429-439. PubMed ID: 36990917
[TBL] [Abstract][Full Text] [Related]
15. CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.
Jarząbek T; Rucińska M; Rogowski W; Lewandowska M; Tujakowski J; Habib M; Kowalczyk A; Byszek A; Dziadziuszko R; Nawrocki S
Mol Diagn Ther; 2015 Apr; 19(2):79-89. PubMed ID: 25721848
[TBL] [Abstract][Full Text] [Related]
16. [Prevention and treatment of mucocutaneous adverse reactions associated with epidermal growth factor receptor inhibitors].
Jiang L; Xiao K; Long H
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Jan; 56(1):87-94. PubMed ID: 35092997
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
18. Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer.
Parma J; Pavlick A; Schiff R; Osborne CK; Chang JC; Rimawi M; Trivedi MV
Pharmacotherapy; 2013 Oct; 33(10):1126-9. PubMed ID: 23744830
[TBL] [Abstract][Full Text] [Related]
19. EGFR inhibitor-induced skin reactions: differentiating acneiform rash from superimposed bacterial infections.
Braden RL; Anadkat MJ
Support Care Cancer; 2016 Sep; 24(9):3943-50. PubMed ID: 27117557
[TBL] [Abstract][Full Text] [Related]
20. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
Luu M; Boone SL; Patel J; Sullivan P; Rademaker AW; Balagula Y; Lacouture ME
Clin Exp Dermatol; 2011 Oct; 36(7):733-8. PubMed ID: 21689147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
